EUCTR2013-002505-62-GB进行中（未招募）1 期
SarCaBon: A randomised phase II trial of Saracatinib versus placebo for cancer-induced bone pain - SarCaBon: Saracatinib versus placebo for cancer-induced bone pain
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Able to give written informed consent and willing to follow the study protocol.
- •2.Age = 16 years.
- •3.Cytologically or histologically confirmed solid tumours of known primary site with painful bone metastases and poor control of bone pain
- •4.WHO performance status = 2
- •5.Average baseline pain score = 4 and = 9 on a 0-10 numerical scale recorded over at least two separate days
- •6.Adequate baseline haematological, hepatic and renal function, defined as follows:
- •Absolute neutrophil count = 1.5 x 109/L, Haemoglobin >9.0 g/dL (can be after transfusion), Platelet count = 100 x 109/L, Bilirubin = 1.5 x ULN, ALT or AST = 2.5 x ULN (= 5 x ULN if liver metastases), Creatinine = 1.5 x ULN,
- •7.Ability to take and absorb oral medications.
- •8.Female patients of childbearing potential (i.e. pre-menopausal females, females who have been menopausal for < 1 year and not surgically sterilized) must provide a negative pregnancy test (serum) = 7 days before study treatment begins and must agree to practice effective contraceptive measures (oral contraceptive pill, intrauterine device or diaphragm with spemicide) plus condoms during the study and for 30 days after last dose of saracatinib.
- •9.Male patients with a partner of child-bearing potential (who is not using an acceptable highly effective method of contraception) or a pregnant partner must use effective contraceptive measures (see 8) plus condoms during the study and for 3 months after the last dose of saracatinib. Patients should abstain from sperm donation during the study and for 3 months after the last dose of saracatinib.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 1
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 16
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 6
排除标准
- •1.Life expectancy < 3 months.
- •2.Previous or planned radiotherapy at site of pain.
- •3.Unstable cardiac disease in last 3 months.
- •4.History of interstitial lung disease (bilateral, diffuse parenchymal lung disease) in view of known saracatinib-related pneumonitis.
- •5.Unable to discontinue any medication with known moderate or potent inhibitory effect on CYP3A4, or is a substrate of CYP3A4.
- •6.Concomitant cytotoxic chemotherapy unless established on maintenance treatment for > 6 weeks (not in a clinical trial).
- •7.Unable to understand written or spoken English as the primary outcome is dependent on completion of the BPI-SF questionnaire.
研究者
相似试验
已完成
2 期
SarCaBon: a randomised phase II trial of saracatinib versus placebo for cancer-induced bone paiCancerISRCTN60942134Sheffield Teaching Hospitals NHS Trust (UK)13
进行中（未招募）
1 期
A randomised placebo-controlled trial of saracatinib (AZD0530) plus weekly paclitaxel in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. - SaPPrOCPlatinum-resistant ovarian, fallopian tube or primary peritoneal cancer. The relevant MedDRA codes for recurrent ovarian cancer and fallopian tube cancer are given below.MedDRA version: 14.1 Level: PT Classification code 10066697 Term: Ovarian cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1 Level: PT Classification code 10016180 Term: Fallopian tube cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-017171-13-GBniversity College London107
已完成
2 期
SarCaBon: A Randomised Phase II Trial of Saracatinib Versus Placebo for Cancer-induced Bone PainCancerNCT02085603Sheffield Teaching Hospitals NHS Foundation Trust12
已完成
2 期
Saracatinib (AZD0530) plus weekly paclitaxel in platinum-resistant ovarian, fallopian tube or primary peritoneal cancerOvarian cancerCancerISRCTN32163062niversity College London (UCL) (UK)107
已完成
2 期
Saracatinib and Paclitaxel in Platinum-resistant Ovarian CancerFallopian Tube CancerPrimary Peritoneal CancerOvarian CancerNCT01196741University College, London107